BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase I/II clinical trial in advanced solid tumors.

XORTX Therapeutics Inc. announces that further to its news release dated August 13, 2021 the Company will complete a share consolidation of the issued and outstanding common shares of the Company on the basis of 11.74 pre-consolidation common shares for each one post-consolidation common share, as approved at the meeting of shareholders held on September 2, 2021.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv).

Seagen Inc. and Genmab A/S announced that the U.S. Food and Drug Administration has granted accelerated approval to TIVDAK™, the first and only approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Telix Pharmaceuticals Limited has welcomed the Society of Nuclear Medicine and Molecular Imaging updated Appropriate Use Criteria for prostate specific membrane antigen positron emission tomography imaging.

Astrotech Corporation (Nasdaq: ASTC) reported its financial results for the fiscal year ended June 30, 2021.

Actinium Pharmaceuticals, Inc. today announced that it will present at four upcoming investor conferences.

Novan, Inc. will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:00 AM ET.

Neurelis, Inc. announced today that it has initiated a clinical program to investigate the use of VALTOCO® (diazepam nasal spray) in children with epilepsy aged two to five as a treatment for seizure clusters.